UY35082A - Sustancia portadora de oxigeno basada en la hemoglobina que contiene una composicion farmaceutica para el tratamiento del cancer y la la prevencion de la recurrencia del cancer - Google Patents

Sustancia portadora de oxigeno basada en la hemoglobina que contiene una composicion farmaceutica para el tratamiento del cancer y la la prevencion de la recurrencia del cancer

Info

Publication number
UY35082A
UY35082A UY35082A UY35082A UY35082A UY 35082 A UY35082 A UY 35082A UY 35082 A UY35082 A UY 35082A UY 35082 A UY35082 A UY 35082A UY 35082 A UY35082 A UY 35082A
Authority
UY
Uruguay
Prior art keywords
cancer
oxygen carrier
pharmaceutical composition
prevention
treatment
Prior art date
Application number
UY35082A
Other languages
English (en)
Inventor
Bing Lou Wong
Norman Fung Man Wai
Sui Yi Kwok
Sze Hang Lau
Original Assignee
Vision Global Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vision Global Holdings Ltd filed Critical Vision Global Holdings Ltd
Publication of UY35082A publication Critical patent/UY35082A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/38—Silver; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención proporciona una composición farmacéutica que contiene un portador de oxígeno basado en la hemoglobina para tratar el cáncer, prevenir la recurrencia y la metástasis de un tumor canceroso. La composición se puede utilizar sola o en combinación con al menos un agente quimioterapéutico tal como 5FU, bortezomib, doxorrubicina, cisplatino, o cualquier combinación de los mismos. El portador de oxígeno basado en la hemoglobina en la composición es capaz de apuntar a un receptor de superficie expresado en las células cancerosas y facilitar la absorción de tanto el portador de oxígeno como el agente quimioterapéutico.
UY35082A 2012-10-12 2013-10-14 Sustancia portadora de oxigeno basada en la hemoglobina que contiene una composicion farmaceutica para el tratamiento del cancer y la la prevencion de la recurrencia del cancer UY35082A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261712853P 2012-10-12 2012-10-12
US13/713,031 US20140106004A1 (en) 2012-10-12 2012-12-13 Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence

Publications (1)

Publication Number Publication Date
UY35082A true UY35082A (es) 2014-07-31

Family

ID=50475529

Family Applications (1)

Application Number Title Priority Date Filing Date
UY35082A UY35082A (es) 2012-10-12 2013-10-14 Sustancia portadora de oxigeno basada en la hemoglobina que contiene una composicion farmaceutica para el tratamiento del cancer y la la prevencion de la recurrencia del cancer

Country Status (22)

Country Link
US (2) US20140106004A1 (es)
EP (1) EP2906222A4 (es)
JP (1) JP6113850B2 (es)
KR (1) KR20150065881A (es)
CN (1) CN104717966B (es)
AP (1) AP2015008315A0 (es)
AR (1) AR093023A1 (es)
AU (1) AU2013329121B2 (es)
BR (1) BR112015007475A2 (es)
CA (1) CA2884521C (es)
CL (1) CL2015000897A1 (es)
EA (1) EA201500301A1 (es)
HK (1) HK1206281A1 (es)
IL (1) IL237763A (es)
MA (1) MA37994A2 (es)
MX (1) MX367562B (es)
PH (1) PH12015500562A1 (es)
SG (3) SG11201502133SA (es)
TW (1) TW201414489A (es)
UY (1) UY35082A (es)
WO (1) WO2014059199A1 (es)
ZA (1) ZA201501949B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9636404B2 (en) * 2013-05-13 2017-05-02 Vision Global Holdings Ltd. Pharmaceutical composition comprising modified hemoglobin-based therapeutic agent for cancer targeting treatment and diagnostic imaging
WO2015192020A1 (en) 2014-06-13 2015-12-17 Children's Medical Center Corporation Products and methods to isolate mitochondria
US9814759B2 (en) * 2014-07-02 2017-11-14 Cheer Global Ltd. Pharmaceutical composition comprising recombinant hemoglobin protein or subunit-based therapeutic agent for cancer targeting treatment
US11903974B2 (en) 2015-11-30 2024-02-20 Flagship Pioneering Innovations V, Inc. Methods and compositions relating to chondrisomes from cultured cells
ES2927427T3 (es) 2016-01-15 2022-11-04 Childrens Medical Ct Corp Uso terapéutico de mitocondrias y agentes mitocondriales combinados
CA3028589A1 (en) * 2016-06-21 2017-12-28 Therapure Biopharma Inc. Hemoglobin-targeted drug delivery for the treatment of cancer
CA3060509A1 (en) * 2017-04-21 2018-10-25 Federica Sotgia Targeting hypoxic cancer stem cells (cscs) with doxycycline: implications for improving anti-angiogenic therapy
US11197872B2 (en) 2017-04-21 2021-12-14 Lunella Biotech, Inc. Vitamin C and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (CSCs)
CR20190524A (es) 2017-05-19 2020-01-10 Lunella Biotech Inc Antimitoscinas: inhibidores específicos de la biogénesis mitocondrial para erradicar células madre cancerosas
US12006553B2 (en) 2017-05-19 2024-06-11 Lunella Biotech, Inc. Companion diagnostics for mitochondrial inhibitors
CR20200033A (es) 2017-06-26 2020-03-05 Lunella Biotech Inc Mitocetoscinas: agentes terapéuticos basados en mitocondrias que fijan como objetivo el metabolismo de cetonas en células cancerosas
WO2019124423A1 (ja) * 2017-12-19 2019-06-27 国立大学法人 岡山大学 がんの進行抑制、治療、予防及び／又は再発予防剤
CN111558032B (zh) * 2020-05-19 2023-08-22 中国科学院宁波材料技术与工程研究所 一种蛋白纳米药物及其制备方法与应用
CN114344263B (zh) * 2022-02-21 2023-08-01 杭州普略生物科技有限公司 一种用于靶向巨噬细胞增强肿瘤治疗效果的纳米蛋白胶束及其制备方法和应用
KR20230141306A (ko) 2022-03-31 2023-10-10 충남대학교산학협력단 저산소증 완화능을 갖는 페길화 헤모글로빈 나노클러스터를 포함하는 항암 화학-광역학 치료용 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478806A (en) * 1989-11-22 1995-12-26 Enzon, Inc. Enhancement of antitumor therapy with hemoglobin-based conjugates
CA2236344A1 (en) * 1998-04-30 1999-10-30 Hemosol Inc. Hemoglobin-haptoglobin complexes
US20050164915A1 (en) * 2002-04-01 2005-07-28 Sangart, Inc. Compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin
US20050202559A1 (en) * 2002-10-29 2005-09-15 Scott Pownall Cancer treatment by metabolic modulations
EP2389068A4 (en) * 2009-01-23 2012-07-18 Cancer Rec Tech Ltd HEMGE OF THE HEDGEHOG SIGNAL PATH
RU2589254C2 (ru) * 2009-06-09 2016-07-10 ПРОЛОНГ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Композиции гемоглобина
MX2012000383A (es) * 2009-07-07 2012-06-01 Normoxys Inc Método para reducir la resistencia a terapias multidroga utilizando tripirofosfato de inositol.
US8808748B2 (en) * 2010-04-20 2014-08-19 Vindico NanoBio Technology Inc. Biodegradable nanoparticles as novel hemoglobin-based oxygen carriers and methods of using the same
US7989593B1 (en) * 2010-05-27 2011-08-02 Bing Lou Wong Method for the preparation of a high-temperature stable oxygen-carrier-containing pharmaceutical composition and the use thereof
US8048856B1 (en) * 2010-06-23 2011-11-01 Billion King, Ltd. Treatment methods using a heat stable oxygen carrier-containing pharmaceutical composition
US20110319332A1 (en) * 2010-06-23 2011-12-29 Bing Lou Wong Treatment methods using a heat stable oxygen carrier-containing pharmaceutical composition
US7932356B1 (en) * 2010-06-23 2011-04-26 Bing Lou Wong Method for the preparation of a heat stable oxygen carrier-containing pharmaceutical composition

Also Published As

Publication number Publication date
AU2013329121A1 (en) 2015-04-09
EA201500301A1 (ru) 2015-08-31
SG10201608747RA (en) 2016-12-29
CA2884521A1 (en) 2014-04-17
HK1206281A1 (en) 2016-01-08
AR093023A1 (es) 2015-05-13
AP2015008315A0 (en) 2015-03-31
EP2906222A1 (en) 2015-08-19
CL2015000897A1 (es) 2015-08-21
SG10201607846PA (en) 2016-11-29
US9056098B2 (en) 2015-06-16
MX367562B (es) 2019-08-27
WO2014059199A8 (en) 2014-05-30
JP2015534946A (ja) 2015-12-07
CN104717966A (zh) 2015-06-17
WO2014059199A1 (en) 2014-04-17
US20140303085A1 (en) 2014-10-09
PH12015500562B1 (en) 2015-05-04
TW201414489A (zh) 2014-04-16
BR112015007475A2 (pt) 2017-08-08
SG11201502133SA (en) 2015-04-29
AU2013329121B2 (en) 2017-05-25
MA37994A2 (fr) 2016-06-30
CN104717966B (zh) 2018-08-24
PH12015500562A1 (en) 2015-05-04
EP2906222A4 (en) 2016-06-22
IL237763A (en) 2017-07-31
JP6113850B2 (ja) 2017-04-12
US20140106004A1 (en) 2014-04-17
CA2884521C (en) 2018-05-01
ZA201501949B (en) 2016-01-27
MX2015004512A (es) 2015-12-01
KR20150065881A (ko) 2015-06-15

Similar Documents

Publication Publication Date Title
UY35082A (es) Sustancia portadora de oxigeno basada en la hemoglobina que contiene una composicion farmaceutica para el tratamiento del cancer y la la prevencion de la recurrencia del cancer
CY1121038T1 (el) Θεραπεια καρκινου μαστου
BR112015016681A8 (pt) uso de nanopartículas compreendendo paclitaxel e uma albumina, kit, medicamento, composição e forma de dosagem unitária para tratamento de câncer pancreático
CR20150376A (es) Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos
CO2017007662A2 (es) Terapias de combinación para el tratamiento de cánceres
ECSP15026557A (es) Compuestos y sus métodos de empleo
ECSP15030799A (es) Compuestos sustituidos de pirrolopirimidina, composiciones de los mismos, y métodos de tratamiento con los mismos
CR20120528A (es) Métodos para tratar el cáncer
CR11687A (es) Terapia de combinación de un anticuerpo anti-cd20 de tipo ii con citotoxicidad celular dependiente de anticuerpos (ccda) aumentada
DOP2015000108A (es) Compuestos de pirrolopirimidina como inhibidores de quinasas
CL2013000018A1 (es) Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros.
NI201200030A (es) Tratamiento anticancerígeno con una combinación de taxanos y 13-dexosiantraciclinas.
CO6670568A2 (es) Métodos de terapia combinada para tratar enfermedades profilerativas
CO7180225A2 (es) Tratamientos de combinación para melanoma que comprenden la administración de cobimetinib y vemurafenib
NI201400111A (es) Tratamiento del cáncer con inhibidores tor cinasa
MX362001B (es) Composición farmacéutica que comprende un agente terapéutico a base de hemoglobina modificada para tratamiento dirigido al cáncer e imagenología diagnóstica.
UY34076A (es) Composición farmacéutica que contiene volasertib en dosificación mejorada y sus usos contra tumores sólidos avanzados
CL2014000053A1 (es) Uso de una composición que contiene un portador de oxígeno no polimérico de hemoglobina tetramérica entrecruzada con una concentración de dímeros indetectablepara la fabricación de un medicamento para reducir la recurrencia de tumores cancerosos y/o minimizar la metástasis de células tumorales en un mamífero; composición que comprende dicha hemoglobina.
CO6761366A2 (es) Composiciones farmacéuticas para el tratamiento de glioma maligno
NI201100228A (es) Procedimientos de uso del factor liberador de corticotropina para el tratamiento de cáncer.
PL414021A1 (pl) Formulacja farmaceutyczna zawierająca izotiocyjaniany i doksorubicynę do zastosowania w leczeniu nowotworów
EA201201654A1 (ru) Противоопухолевое средство (варианты)
WO2013013075A3 (en) Peptides shared among lethal cancers and therapeutic compositions comprising said peptides
MY186484A (en) Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence
EA201201655A1 (ru) Противоопухолевое средство (варианты)

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20210617